Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

(2018) H S Rugo et al.   ANNALS OF ONCOLOGY

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

(2018) Wolfgang Janni et al.   BREAST CANCER RESEARCH AND TREATMENT

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting CDK4/6 in patients with cancer

(2016) Erika Hamilton et al.   CANCER TREATMENT REVIEWS

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

(2016) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard

(2016) Antonio C. Wolff   NEW ENGLAND JOURNAL OF MEDICINE

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

(2015) N. I. Cherny et al.   ANNALS OF ONCOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

The iMTA Productivity Cost Questionnaire

(2015) Clazien Bouwmans et al.   VALUE IN HEALTH

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

(2013) Dorien J. A. Lobbezoo et al.   BREAST CANCER RESEARCH AND TREATMENT

Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study

(2012) M. F. Janssen et al.   QUALITY OF LIFE RESEARCH

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

(2009) E. D. Saad et al.   ANNALS OF ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER